Stock HLVX HILLEVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company HilleVax, Inc.

Equities

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-01 EDT 		5-day change 1st Jan Change
13.56 USD +2.73% Intraday chart for HilleVax, Inc. +7.79% -15.51%
04-05 Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing MT
03-21 Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating MT

Business Summary

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Number of employees: 90

Managers

Managers TitleAgeSince
Robert Hershberg CEO
 Chief Executive Officer 61 20-02-29
Shane Maltbie DFI
 Director of Finance/CFO 42 21-11-30
Anju Chatterji CTO
 Chief Tech/Sci/R&D Officer - 21-12-31
Astrid Borkowski CTO
 Chief Tech/Sci/R&D Officer 54 21-02-28
Paul S. Bavier ADM
 Chief Administrative Officer 51 20-12-31
Ozzie Berger LAW
 General Counsel - 23-01-08
Aditya Kohli PRN
 Corporate Officer/Principal 36 21-01-31

Members of the board

Members of the board TitleAgeSince
Robert Hershberg CEO
 Chief Executive Officer 61 20-02-29
Jeryl Hilleman BRD
 Director/Board Member 66 21-03-31
Shelley Chu BRD
 Director/Board Member 54 21-07-31
Patrick Heron BRD
 Director/Board Member 53 20-02-29
Julie Gerberding BRD
 Director/Board Member 69 21-03-31
Jaime Sepulveda BRD
 Director/Board Member 70 21-01-31
Aditya Kohli PRN
 Corporate Officer/Principal 36 21-01-31
Gary Dubin BRD
 Director/Board Member 67 22-02-28
Nanette Cocero BRD
 Director/Board Member - 23-05-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 50,552,358 46,031,192 ( 91.06 %) 831,415 ( 1.645 %) 91.06 %

Shareholders

NameEquities%Valuation
Frazier Life Sciences Management LP
17.19 %
8,544,187 17.19 % 142 M $
TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.53 %
6,724,000 13.53 % 112 M $
Deerfield Management Co. LP (Private Equity)
8.057 %
4,004,231 8.057 % 67 M $
Deep Track Capital LP
5.835 %
2,900,000 5.835 % 48 M $
Lightspeed Management Co LLC
4.655 %
2,313,432 4.655 % 38 M $
Venrock Associates
4.175 %
2,075,000 4.175 % 35 M $
Franklin Advisers, Inc.
3.715 %
1,846,396 3.715 % 31 M $
Abingworth LLP
3.699 %
1,838,486 3.699 % 31 M $
BlackRock Advisors LLC
3.421 %
1,700,182 3.421 % 28 M $
Vanguard Fiduciary Trust Co.
2.947 %
1,464,840 2.947 % 24 M $

Company contact information

HilleVax, Inc.

321 Harrison Avenue Suite 500

02118, Boston

+

http://www.hillevax.com
address HilleVax, Inc.(HLVX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.56 USD
Average target price
29 USD
Spread / Average Target
+113.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HILLEVAX, INC. Stock HilleVax, Inc.
-15.51% 636M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HLVX Stock
  4. Company HilleVax, Inc.